ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years
Mehran Taherian
Matched on OpenAlex author ID A5113879709. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2022: 2 papers · 2023: 1 paper · 2024: 1 paper
Papers 4
- The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Co-author DOI 10.3390/cancers16193312↗
- Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. First author DOI 10.1097/pas.0000000000002013↗
- Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a narrative review. Co-author DOI 10.21037/cco-21-175↗
- Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers. Co-author DOI 10.3390/cells11193068↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Huamin Wang · 4 shared papers, 2022–2024 · strength 0.91
- Paper Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a na… DOI 10.21037/cco-21-175↗
- Paper Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers. DOI 10.3390/cells11193068↗
- Paper The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvan… DOI 10.3390/cancers16193312↗
- Matthew H. G. Katz · 2 shared papers, 2023–2024 · strength 0.32
- Paper The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvan… DOI 10.3390/cancers16193312↗
- Paper Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuv… DOI 10.1097/pas.0000000000002013↗
- Dan Zhao · 2 shared papers, 2023–2024 · strength 0.32
- Paper The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvan… DOI 10.3390/cancers16193312↗
- Paper Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuv… DOI 10.1097/pas.0000000000002013↗
- Hua Wang · 2 shared papers, 2023–2024 · strength 0.32
- Paper The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvan… DOI 10.3390/cancers16193312↗
- Paper Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuv… DOI 10.1097/pas.0000000000002013↗
- Deyali Chatterjee · 2 shared papers, 2023–2024 · strength 0.32
- Paper The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvan… DOI 10.3390/cancers16193312↗
- Paper Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuv… DOI 10.1097/pas.0000000000002013↗
- Robert A. Wolff · 2 shared papers, 2023–2024 · strength 0.32
- Paper The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvan… DOI 10.3390/cancers16193312↗
- Paper Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuv… DOI 10.1097/pas.0000000000002013↗
- Naruhiko Ikoma · 2 shared papers, 2023–2024 · strength 0.32
- Paper The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvan… DOI 10.3390/cancers16193312↗
- Paper Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuv… DOI 10.1097/pas.0000000000002013↗
- Laura R. Prakash · 2 shared papers, 2023–2024 · strength 0.32
- Paper The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvan… DOI 10.3390/cancers16193312↗
- Paper Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuv… DOI 10.1097/pas.0000000000002013↗
- Michael P. Kim · 2 shared papers, 2023–2024 · strength 0.32
- Paper The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvan… DOI 10.3390/cancers16193312↗
- Paper Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuv… DOI 10.1097/pas.0000000000002013↗
- Anirban Maitra · 2 shared papers, 2023–2024 · strength 0.32
- Paper The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvan… DOI 10.3390/cancers16193312↗
- Paper Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuv… DOI 10.1097/pas.0000000000002013↗
- Eugene Jon Koay · 2 shared papers, 2023–2024 · strength 0.32
- Paper The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvan… DOI 10.3390/cancers16193312↗
- Paper Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuv… DOI 10.1097/pas.0000000000002013↗
- Ching-Wei David Tzeng · 2 shared papers, 2023–2024 · strength 0.32
- Paper The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvan… DOI 10.3390/cancers16193312↗
- Paper Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuv… DOI 10.1097/pas.0000000000002013↗
- Yi Tat Tong · 1 shared paper, 2024 · strength 0.18
- Aaron J. Sohn · 1 shared paper, 2023 · strength 0.15
- Ryan Sun · 1 shared paper, 2023 · strength 0.15
- Jeffrey E. Lee · 1 shared paper, 2023 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.